Pharma & Biotech Mergers & Acquisitions News
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Some of biopharma's biggest companies announced acquisitions in March and April. 7 May 2021
Biotechnology
Irish rare diseases firm Amryt Pharma has signed a definitive agreement to acquire US-headquartered Chiasma in an all-stock combination valued at around $330 million. 6 May 2021
Pharmaceutical
US pharma giant Merck & Co has detailed plans for the Organon spinoff. 5 May 2021
Biotechnology
Eikon Therapeutics, a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. 5 May 2021
Biotechnology
Life-cycle investment firm RTW Investments and Dutch biotech ProQR Therapeutics today announced that Yarrow Biotechnology, a company newly created by RTW, has in-licensed exclusive rights to ProQR’s antisense oligonucleotide (ASO) technology to develop and commercialize potential therapies for an undisclosed non-ophthalmic target. 4 May 2021
Biotechnology
The launch of French drug discovery company NovoBiome has been announced. 4 May 2021
Biotechnology
Newly-established Swiss biotech MoonLake Immunotherapeutics has in-licensed the tri-specific nanobody sonelokimab (M1095/ALX 0761) from Germany’s Merck KGaA (MRK: DE). 4 May 2021
Biotechnology
Switzerland-based biopharma Roivant Sciences and Montes Archimedes Acquisition, a special purpose acquisition company (SPAC) sponsored by Patient Square Capital, have entered into a definitive business combination agreement. 4 May 2021
Biotechnology
US pharma giant Pfizer said yesterday that it has acquired San Diego-based Amplyx Pharmaceuticals, a privately-held biotech dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. 29 April 2021
Biotechnology
Anavo Therapeutics, a Netherlands-based company that is aiming to unlock the full therapeutic potential of human phosphatase biology, debuted today with a 20 million euros (~$24 million) seed financing from M Ventures, INKEF, Taiho Ventures, and Bioqube Ventures. 22 April 2021
Biotechnology
Ocular diseases focussed genomics medicines company SparingVision has entered into a definitive agreement to acquire fellow French biotech firm GAMUT Therapeutics, which has unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa (RP). 20 April 2021
Biotechnology
The USA’s largest biotech firm Amgen on Friday announced it has completed its planned acquisition of Five Prime Therapeutics for $1.9 billion. 19 April 2021
Biotechnology
US biotech Tango Therapeutics has signed a deal with BCTG Acquisition, a special-purpose acquisition company, or SPAC, sponsored by San Diego's Boxer Capital, to go public through a reverse merger. 14 April 2021
Biotechnology
French pharma major Sanofi late Friday revealed it has acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells. 10 April 2021
Biotechnology
Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, says it has acquired fellow UK-based ADC Biotechnology, a bioconjugation development services business specializing in antibody drug conjugates (ADCs). 6 April 2021
Biotechnology
Notable regulatory news last week included Bristol Myers Squibb and bluebird bio gaining US clearance for their Abecma, marking the first Food and Drug Administration approval for a CAR-T therapy in the treatment of multiple myeloma. Also, AbbVie had its new drug application for atogepant, a new migraine prevention candidate, accepted for review by the FDA. On the M&A front, Amgen announced last Wednesday that it is buying Rodeo Therapeutics and its 15-PGDH program in regenerative medicine. BioNTech and Pfizer presented more positive news on their COVID-19 vaccine BNT162b2, this time on its efficacy in children, while Johnson & Johnson hit a production quality snag relating to its COVID-19 Vaccine Janssen. 4 April 2021
Generics
Piramal Pharma Limited’s contract development and manufacturing organization (CDMO), Piramal Pharma Solutions (PPS), has entered into an agreement to acquire a 100% stake in fellow India-based Hemmo Pharmaceuticals. 1 April 2021
Biotechnology
US biotech major Amgen has entered into an agreement to acquire Rodeo, a privately held biopharmaceutical company based in Seattle that develops small-molecule therapies designed to promote regeneration and repair of multiple tissues. 31 March 2021
Biotechnology
Life sciences investment trust Syncona has invested $42.3 million UK-based Gyroscope Therapeutics, a clinical-stage gene therapy company focused on diseases of the eye, in an $148.0 million (£107.8 million) Series C financing. 26 March 2021
Pharmaceutical
There has never been a better time to raise money for companies in the life sciences sector, according to Ben Long, partner at UK-headquartered private equity firm Inflexion. 23 March 2021
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Biotechnology
California, USA-based Lyell Immunopharma (Nasdaq: LYEL) has entered into a definitive agreement to acquire privately-held US CAR-T company ImmPACT Bio. 26 October 2024
Biotechnology
Mumbai-based Mankind Pharma has completed its acquisition of Bharat Serums and Vaccines (BSV), adding to its portfolio in the women’s health and fertility market. 24 October 2024
Biotechnology
Ocuphire Pharma has announced its acquisition of Opus Genetics, a clinical-stage gene therapy company focused on treating inherited retinal diseases. 24 October 2024
Biotechnology
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co 23 October 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Pharmaceutical
Last week’s significant news included Denmark-based CNS drugmaker Lundbeck reaching agreement to acquire US firm Longboard Pharmaceuticals, along with its bexicaserin, for $2.6 billion. Also, US pharma giant Pfizer entered into a deal with TRIANA Biomedicines to develop molecular glue degraders. On the regulatory front, the US Food and Drug Administration (FDA) last week approved Novocure’s key product Optune Lua for lung cancer patients. Also, German biotech BioNTech and its US partner OncoC4 received a partial clinical hold from the FDA on the Phase III trial of gotistobart in lung cancer. The European Medicines Agency’s human health committee, CHMP, Reaffirmed its non-approval of PTC Therapeutic’s Translarna. 20 October 2024
Biotechnology
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and France-based Kiji Therapeutics, a specialist in induced pluripotent stem cells-mesenchymal stem cells (IPSC-MSC) engineered cell therapies for inflammatory diseases, are to merge. 18 October 2024
Biotechnology
Danish CNS specialist Lundbeck today revealed that it has reached to acquire Longboard Pharmaceuticals. 15 October 2024
Biotechnology
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze